Kenneth Pfeiffer, a primary care physician and diabetes clinic co-director at Mount Sinai, defends GLP-1 receptor agonists for diabetes and obesity management. Keri Blum, also from Mount Sinai, highlights SGLT2 inhibitors as beneficial for heart and kidney health. Tracy Rabin, from Yale, emphasizes the practical use of metformin considering cost and tolerability. They delve into the complexities of choosing diabetes medications, weighing factors like A1c reduction, side effects, and patient-specific needs, including obesity and comorbidities.
